Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
169.6 USD | +0.61% | +4.91% | +9.15% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.15% | 298B | |
+46.11% | 754B | |
+41.83% | 630B | |
-6.16% | 352B | |
+20.13% | 331B | |
+18.74% | 250B | |
+12.15% | 217B | |
-0.57% | 216B | |
+6.26% | 164B | |
0.00% | 163B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target